Laboratorio Reig Jofre (0RB1) Stock Overview
A pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmacy, food, and animal food. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
0RB1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.69 |
| 52 Week High | €3.38 |
| 52 Week Low | €2.50 |
| Beta | 1.05 |
| 1 Month Change | -9.12% |
| 3 Month Change | -7.24% |
| 1 Year Change | -3.24% |
| 3 Year Change | -2.18% |
| 5 Year Change | n/a |
| Change since IPO | -54.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RB1 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.5% | 3.3% | 2.0% |
| 1Y | -3.2% | 28.0% | 16.1% |
Return vs Industry: 0RB1 underperformed the UK Pharmaceuticals industry which returned 28.4% over the past year.
Return vs Market: 0RB1 underperformed the UK Market which returned 15.3% over the past year.
Price Volatility
| 0RB1 volatility | |
|---|---|
| 0RB1 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RB1 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0RB1's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,426 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmacy, food, and animal food. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| 0RB1 fundamental statistics | |
|---|---|
| Market cap | €218.13m |
| Earnings (TTM) | €4.25m |
| Revenue (TTM) | €330.34m |
Is 0RB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RB1 income statement (TTM) | |
|---|---|
| Revenue | €330.34m |
| Cost of Revenue | €139.83m |
| Gross Profit | €190.51m |
| Other Expenses | €186.26m |
| Earnings | €4.25m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.052 |
| Gross Margin | 57.67% |
| Net Profit Margin | 1.29% |
| Debt/Equity Ratio | 24.1% |
How did 0RB1 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 08:49 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laboratorio Reig Jofre, S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Francisco Ruiz | BNP Paribas |
| Alfredo Echevarria Otegui | Lighthouse-IEAF Servicios de Analisis |
| Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |